4.jpeg)
The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across the United States and Mexico. Additional analyses of the trial are ongoing, according to the company, and will be submitted to peer-reviewed journals for publication.
The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across the United States and Mexico. Additional analyses of the trial are ongoing, according to the company, and will be submitted to peer-reviewed journals for publication.
139.jpeg)
260.jpeg)
259.jpeg)
258.jpeg)
